First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of ...

Traditional autologous CAR-T therapies ... The institute is pioneering an off-the-shelf, allogeneic cell therapy approach, which involves creating treatments from donor cells rather than a ...

Cell therapy is ... two basic categories: autologous cell therapies, which involve removing a patient’s cells, modifying them, and returning them to the body, and allogeneic cell therapies ...

Swedish cancer patients treated with CAR T-cell therapy show better survival rates and fewer side effects than seen in ...

I’m upbeat about cell therapy development for Parkinson ... and whether to use allogeneic or autologous cells.

High-dose chemotherapy and HSCT can provide long-term benefits in patients with MCL, a retrospective study suggests.

The CardiAMP-HF trial of the autologous bone marrow mononuclear cell therapy (CardiAMP ... they’re not sensitized by allogeneic cells.” The primary outcome was a hierarchical composite ...

Challenges for all allogeneic cell therapy developers include achieving ... and durability of approved autologous CAR T cell therapies.” By delaying the data readout, both programs will be ...

There have been no treatment emergent major adverse cardiac events observed nor has there been any clinical evidence of immune reactions to the allogeneic cells implanted. “We are pleased with ...